Literature DB >> 17703775

[Pharmacokinetics and biodistribution of 3H-norcantharidin in mice].

Chun-Min Wei1, Ben-Jie Wang, Ya Ma, Zi-Ping Sun, Xiao-Li Li, Rui-Chen Guo.   

Abstract

A single dose of 3H-norcantharidin solution was intragastrically given, blood, tissues, urine and feces were collected as scheduled, and radioactivity in these samples was determined by tritium tracing method to investigate the pharmacokinetics, tissue distribution and excretion of norcantharidin in Kunming mice. The pharmacokinetic characteristics of norcantharidin were evaluated by DAS version 2.0. The blood concentration reached to maximum 0. 5 h after intragastric administration. The radioactivity in tissues was high in small intestine, gallbladder, stomach, adrenal gland, kidney, heart and uterus 15 minutes after administration, descending with time, and high in gallbladder, adrenal gland and uterus 3 hours post dosing. The 24 h accumulative excretion ratio of urine and feces were 65.40% and 1.33% respectively. 3H-norcantharidin was easily absorbed after orally given to mice, the radioactivity was high and existed for a long-time in gallbladder, adrenal gland and uterus, and low but also existed for a long-time in large intestine, thymus and fat tissue. 3H-norcantharidin was declined quickly in small intestine, stomach, kidney and heart, and occurred rarely in brain. Norcantharidin was excreted mainly by urinary route and seldom in feces, which may be the cause of the urinary stimulation side effects observed. Because the radioactivity measured were the sum of 3H labeled norcantharidin and its metabolites, further studies on the disposition of norcantharidin in mammal animals, on the separation or identification of metabolites and, if any, on their activities, are fairly needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703775

Source DB:  PubMed          Journal:  Yao Xue Xue Bao        ISSN: 0513-4870


  6 in total

1.  Inhibitory effects of norcantharidin against human lung cancer cell growth and migration.

Authors:  Jinling Luan; Huiying Duan; Qian Liu; Kazumi Yagasaki; Guoying Zhang
Journal:  Cytotechnology       Date:  2010-01-20       Impact factor: 2.058

2.  Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action.

Authors:  Yan Huang; Qian Liu; Kun Liu; Kazumi Yagasaki; Guoying Zhang
Journal:  Cytotechnology       Date:  2009-07-15       Impact factor: 2.058

3.  Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS.

Authors:  Xin-Yuan Ding; Cheng-Jiao Hong; Yang Liu; Zong-Lin Gu; Kong-Lang Xing; Ai-Jun Zhu; Wei-Liang Chen; Lin-Seng Shi; Xue-Nong Zhang; Qiang Zhang
Journal:  Int J Nanomedicine       Date:  2012-04-02

Review 4.  Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities.

Authors:  Mu-Su Pan; Jin Cao; Yue-Zu Fan
Journal:  Chin Med       Date:  2020-05-29       Impact factor: 5.455

5.  Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.

Authors:  Jing Zhu; Wei Zhang; Dandan Wang; Suzhen Li; Wei Wu
Journal:  Exp Ther Med       Date:  2018-07-06       Impact factor: 2.447

6.  Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer.

Authors:  Xiu-Yan Li; Qing-Xia Guan; Yu-Zhou Shang; Yan-Hong Wang; Shao-Wa Lv; Zhi-Xin Yang; Rui Wang; Yu-Fei Feng; Wei-Nan Li; Yong-Ji Li
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.